Marizyme logo

Marizyme(OTC) MRZM

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Marizyme last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-04
Marizyme stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-01-26
1 month+0%USD 0.002026-01-26
3 month+0%USD 0.002026-01-26
Year to date+0%USD 0.002025-10-02
1 year+0%USD 0.002025-07-25
3 year-100%USD 0.182023-08-30
5 year-100%USD 1.602021-09-03
Since inception-100%USD 1.742010-05-03

Marizyme Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$183.42K

Net Income (TTM)

-$22.03M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.84 (Low)

Price

$0.00

Volume

3

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 5, 2026

MRZM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Marizyme

Marizyme, Inc. is a life sciences company focused on developing and commercializing innovative medical technologies. The company specializes in products aimed at improving patient outcomes in various medical fields, including vascular surgery and chronic disease management.

Products and Services
  • DuraGraft: A single-application treatment for vascular surgeries
  • Krillase: A protease-based platform for treating severe wounds and burns
  • MATLOC: A digital lab-on-chip device for chronic kidney disease diagnosis
Growth Outlook
  • Expansion into chronic disease management with MATLOC technology
  • Potential market growth in vascular surgery products
  • Ongoing development of Krillase for diverse medical applications
Financial Highlights
  • Q3 2024 net income of -$3.25 million, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $181,535, indicating early-stage product traction
  • Current ratio of 0.042, highlighting liquidity challenges
Marizyme, Inc. is positioned in the biotechnology sector, focusing on innovative solutions that address critical medical needs. The company’s flagship product, DuraGraft, is designed to enhance the performance of vascular grafts, while the Krillase platform aims to tackle severe wounds and other conditions. The development of MATLOC represents a significant step towards integrating technology in chronic disease management, potentially transforming patient care. Despite facing financial challenges, including a negative net income and low liquidity ratios, the company is actively investing in research and development to drive future growth. The recent quarterly results indicate a commitment to advancing its product offerings, which may lead to increased market presence and revenue generation in the long term. Investors may find interest in the company's innovative approach and potential for growth in the evolving healthcare landscape.
AI Generated • Oct 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

David L. Barthel, MBA

Website

www.marizyme.com

Headquarters

Jupiter, FL 33458, US

MRZM Financials

Key Financial Metrics (TTM)

Gross Margin

36.99%

Operating Margin

-5278.10%

Net Income Margin

-10767.77%

Return on Equity

-1089.84%

Return on Capital

-211.76%

Return on Assets

-315.87%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

131.79M

Volume

3

Avg. Volume

0.046

Financials (TTM)

Gross Profit

-$736.33K

Operating Income

-$26.61M

EBITDA

-$11.25M

Operating Cash Flow

-$3.84M

Capital Expenditure

$4.00

Free Cash Flow

-$3.84M

Cash & ST Invst.

$63.73K

Total Debt

$26.66M

Marizyme Performance Analysis

Marizyme annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 210,279N/A
20222022-12-31USD 233,48511.0%
20232023-12-31USD 645,810176.6%
Marizyme sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-17.1%
Q12024-03-31-78.2%
Q22024-06-30-100.0%
Q32024-09-30N/A
Marizyme annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.31N/A
20222022-12-31USD -0.94207.1%
20232023-12-31USD -1.5363.2%
Marizyme sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3167.2%
Q12024-03-3175.2%
Q22024-06-3034.5%
Q32024-09-3051.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$210.78K

-261.5%

Gross Margin

0.00%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.69

N/A

Employees

13

N/A

Net Income

-$1.96M

+94.0%

EBITDA

-$644.00K

+97.4%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$63.73K

-86.6%

Total Debt

$26.66M

+23.4%

Accounts Receivable

$37.88K

-52.0%

Inventory

$26.87K

-72.9%

Long Term Debt

$355.18K

-55.9%

Short Term Debt

$26.30M

+26.5%

Return on Assets

-3.16%

N/A

Return on Invested Capital

54.31%

N/A

Free Cash Flow

-$983.13K

+14.7%

Operating Cash Flow

-$983.13K

+14.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BPTHBio-Path Holdings, Inc.
$0.00+0.00%
HALBHalberd Corporation
$0.00-8.45%
EVFMEvofem Biosciences, Inc.
$0.01+0.00%
ISCOInternational Stem Cell Corporation
$0.28+3.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About MRZM

What is the current price of Marizyme?

Marizyme is trading at $0.00 per share.

What is the 52-week range for Marizyme?

Over the past 52 weeks, Marizyme has traded between $0.00 and $0.00.

How much debt does Marizyme have?

As of the most recent reporting period, Marizyme reported total debt of $20.76M.

How much cash does Marizyme have on hand?

Marizyme reported $148.47K in cash and cash equivalents in its most recent financial results.

What is Marizyme’s dividend yield?

Marizyme does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services